Free Trial
→ A weekly dividend fund holding Nvidia and Palantir (From Investors Alley) (Ad)tc pixel
NASDAQ:BNTX

BioNTech Q3 2026 Earnings Report

BioNTech logo
$96.18 -1.46 (-1.50%)
As of 02:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

BioNTech EPS Results

Actual EPS
N/A
Consensus EPS
$0.84
Beat/Miss
N/A
One Year Ago EPS
N/A

BioNTech Revenue Results

Actual Revenue
N/A
Expected Revenue
$1.20 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioNTech Announcement Details

Quarter
Q3 2026
Date
11/3/2026
Time
Before Market Opens
Conference Call Date
Tuesday, November 3, 2026
Conference Call Time
7:00AM ET

Conference Call Resources

BioNTech Earnings Headlines

Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up
October 5 at 3:02 PM  |  247wallst.comhttps://247wallst.com/investing/2026/10/05/novavax-soars-22-as-sanofi-carries-nuvaxovid-into-vaccination-season-moderna-climbs-8-biontech-ticks-up/?utm_source=snapi
Moderna Surges 8% as Full Melanoma Readout Nears; BioNTech Ticks Up, Pfizer Slips
October 5 at 2:47 PM  |  247wallst.comhttps://247wallst.com/investing/2026/10/05/moderna-surges-8-as-full-melanoma-readout-nears-biontech-ticks-up-pfizer-slips/?utm_source=snapi
Nvidia’s record quarter could send this new type of AI soaring
Nvidia just posted 96.2 billion in revenue for a single quarter, more than Coca-Cola generates in an entire year. The top five hyperscalers, Amazon, Google, Microsoft, Meta, and Oracle, are projected to spend 800 billion on AI this year and 1.3 trillion next year. Jason Bodner, a former Wall Street trader whose system has flagged stocks like Nvidia, Super Micro Computer, and Vertiv before major run ups, says a new light speed technology called Accelerated AI could be next in line for that spending.tc pixel
October 6 at 1:00 AM  |  Brownstone Research (Ad)
BioNTech (NASDAQ: BNTX) CEO sells 34,000 shares in planned stock sale
October 5 at 1:02 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085317
BioNTech SE: Moving Past Covid
October 4 at 9:44 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4951846-biontech-se-moving-past-covid
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Stock Now Rated "Moderate Buy" by Sell-Side Brokerages
October 3 at 3:03 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081939
See More BioNTech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioNTech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioNTech and other key companies, straight to your email.

About BioNTech

BioNTech (NASDAQ:BNTX) SE is a biotechnology company headquartered in Mainz, Germany, focused on developing therapies and vaccines for cancer and other serious diseases. The company’s research platform includes messenger RNA (mRNA), individualized cancer vaccines, immune-modulating therapies, cell therapies, and protein-based therapeutics.

BioNTech is best known for developing the Comirnaty COVID-19 vaccine in collaboration with Pfizer. Comirnaty uses mRNA technology to help stimulate an immune response against COVID-19 and has been distributed in markets around the world. BioNTech continues to advance vaccine programs targeting infectious diseases while expanding its oncology pipeline.

Founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber, BioNTech operates research and development activities in Europe, North America, and other international markets. Şahin serves as chief executive officer, while Türeci is the company’s chief medical officer. The company’s cancer programs include personalized immunotherapies designed to target tumor-specific characteristics.

View BioNTech Profile
Earnings Tools